Erratum: Identification and validation of protein biomarkers of response to neoadjuvant platinum chemotherapy in muscle invasive urothelial carcinoma (PLoS ONE (2015) 10:7 (e0131245) (DOI:10.1371/journal.pone.0131245));Identification and validation of Protein biomarkers of response to neoadjuvant platinum chemotherapy in muscle invasive urothelial carcinoma

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Baras, Alexander S ^a   Gandhi, Nilay ^a   Munari, Enrico ^a   Faraj, Sheila ^a   Shultz, Luciana ^a   Marchionni, Luigi ^a   Schoenberg, Mark ^b   Hahn, Noah ^a   Hoque, Mohammad ^a   Berman, David ^c   Bivalacqua, Trinity J ^a   Netto, George ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; GEMCITABINE; MESSENGER RNA; PROTEIN GDPD3; PROTEIN SPRED1; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CARCINOMA; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYSTECTOMY; FEMALE; GDPD3 GENE; GENE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; MUSCLE INVASIVE UROTHELIAL CARCINOMA; MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PROTEIN ANALYSIS; SPRED1 GENE; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; VALIDATION STUDY; VERY ELDERLY; ANALOGS AND DERIVATIVES; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; MUSCLE TUMOR; NEOADJUVANT THERAPY; PATHOLOGY; SECONDARY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BIOMARKERS, TUMOR; CISPLATIN; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; NEOADJUVANT THERAPY; RNA, MESSENGER; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84942116726     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143990     Document Type: Erratum

References (29)

1. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993 Nov. 4; 329(19):1377-1382. PMID: 8413433
2. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J Clin Oncol 2001 Feb. 1; 19(3):666-675. PMID: 11157016
3. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003 Aug. 28; 349(9):859-866. PMID: 12944571
4. Advanced Bladder Cancer Overview Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev 2005 Apr. 18; (2:) (2): CD005246.
5. Zaid HB, Patel SG, Stimson CJ, Resnick MJ, Cookson MS, Barocas DA, et al. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology 2014 Jan; 83(1):75-80. doi: 10.1016/j.urology.2013.07.072 PMID: 24231210
6. Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kevin Kelly W, et al. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol Oncol 2014 Jul; 32(5):637-644. doi: 10.1016/j.urolonc.2013.12.012 PMID: 24840869
7. Kato Y, Zembutsu H, Takata R, Miya F, Tsunoda T, Obara W, et al. Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profiling. Exp Ther Med 2011 Jan; 2(1):47-56. PMID: 22977468
8. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005 Apr. 1; 11(7):2625-2636. PMID: 15814643
9. Takata R, Obara W, Fujioka T. Study of the prediction system for clinical response to M-VAC neoadjuvant chemotherapy for bladder cancer. Aktuelle Urol 2010 Jan; 41 Suppl 1:S41-5. doi: 10.1055/s-0029-1224655 PMID: 20094952
10. Williams PD, Cheon S, Havaleshko DM, Jeong H, Cheng F, Theodorescu D, et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res 2009 Nov. 1; 69(21):8302-8309. doi: 10.1158/0008-5472. CAN-09-0798 PMID: 19843853
11. Smith SC, Baras AS, Dancik G, Ru Y, Ding KF, Moskaluk CA, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 2011 Feb; 12(2):137-143. doi: 10.1016/S1470-2045 (10) 70296-5 PMID: 21256081
12. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissuebased map of the human proteome. Science 2015 Jan 23; 347(6220):1260419. doi: 10.1126/science. 1260419 PMID: 25613900
13. George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ, et al. P53 Gene and Protein Status: the Role of P53 Alterations in Predicting Outcome in Patients with Bladder Cancer. J Clin Oncol 2007 Dec. 1; 25(34):5352-5358. PMID: 18048815
14. Friedman J, Hastie T, Tibshirani R. Additive Logistic Regression: a Statistical View of Boosting. Annals of Statistics 1998.
15. Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, et al. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 2012 Mar. 1; 18(5):1323-1333. doi: 10.1158/1078-0432. CCR-11-2271 PMID: 22228636
16. Gandhi NM, Baras A, Munari E, Faraj S, Reis LO, Liu JJ, et al. Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. Urol Oncol 2015 Mar. 23.
17. Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA Jr., Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol 2003 Oct; 170(4 Pt 1):1085-1087. PMID: 14501697
18. Sanchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003 Jan; 169(1):110-5; discussion 115. PMID: 12478115
19. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014 Mar. 20; 507(7492):315-322. doi: 10.1038/nature12965 PMID: 24476821
20. Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014 Oct; 4(10):1140-1153. doi: 10.1158/2159-8290. CD-14-0623 PMID: 25096233
21. Ross JS, Wang K, Al-Rohil RN, Nazeer T, Sheehan CE, Otto GA, et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol 2013 Jul. 26.
22. Groenendijk FH, De Jong J, Fransen Van De Putte EE, Michaut M, Schlicker A, Peters D, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol 2015 Jan 27.
23. Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol 2009 Jun; 22 Suppl 2:S96-S118. doi: 10.1038/modpathol.2009.26 PMID: 19494856
24. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct Basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014 Feb. 10; 25(2):152-165. doi: 10.1016/j.ccr.2014.01.009 PMID: 24525232
25. Lindgren D, Frigyesi A, Gudjonsson S, Sjodahl G, Hallden C, Chebil G, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010 May 1; 70(9):3463-3472. doi: 10.1158/0008-5472. CAN-09-4213 PMID: 20406976
26. Lindgren D, Sjodahl G, Lauss M, Staaf J, Chebil G, Lovgren K, et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One 2012;7(6):e38863. doi: 10.1371/journal.pone.0038863 PMID: 22685613
27. McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, et al. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol 2010 Jul-Aug; 28(4):429-440. doi: 10.1016/j.urolonc.2010.04.008 PMID: 20610280
28. Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 2012 Jun. 15; 18(12):3377-3386. doi: 10.1158/1078-0432. CCR-12-0077-T PMID: 22553347
29. Sjodahl G, Lovgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G, et al. Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol 2013 Sep; 183(3):681-691. doi: 10.1016/j. ajpath.2013.05.013 PMID: 23827819